Newly assigned chief executive of GlaxoSmithKline Andrew Witty has delivered his plans for the future of the firm, which include ramping up cost saving initiatives and increasing the focus on consumer products.
He plans to reduce the company’s reliance on prescription drugs in favour of pursuing products such as Lucozade and Panadol. “There are no sacred cows and we’ll be pretty much blind to heritage… a very pragmatic, very return-driven mindset is what you should be expecting from us,” he said. Cost cuts will also be of…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
